Gryphon Financial Partners LLC Sells 1,471 Shares of Danaher Co. (NYSE:DHR)

Gryphon Financial Partners LLC lowered its holdings in Danaher Co. (NYSE:DHR - Free Report) by 51.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,404 shares of the conglomerate's stock after selling 1,471 shares during the quarter. Gryphon Financial Partners LLC's holdings in Danaher were worth $322,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Howard Capital Management Group LLC lifted its position in Danaher by 4.1% in the 3rd quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate's stock valued at $342,000 after acquiring an additional 48 shares in the last quarter. Princeton Global Asset Management LLC lifted its holdings in shares of Danaher by 360.0% in the third quarter. Princeton Global Asset Management LLC now owns 230 shares of the conglomerate's stock valued at $64,000 after purchasing an additional 180 shares in the last quarter. Clear Creek Financial Management LLC bought a new stake in Danaher during the third quarter worth $207,000. Pure Financial Advisors LLC purchased a new stake in Danaher in the 3rd quarter valued at $202,000. Finally, Kanawha Capital Management LLC bought a new position in Danaher during the 3rd quarter valued at $217,000. Institutional investors own 79.05% of the company's stock.

Danaher Price Performance

Shares of DHR traded up $0.23 during midday trading on Tuesday, hitting $205.92. 5,652,379 shares of the company traded hands, compared to its average volume of 4,574,931. The stock has a 50-day moving average of $224.11 and a 200-day moving average of $244.31. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a one year low of $196.80 and a one year high of $281.70. The firm has a market cap of $147.17 billion, a P/E ratio of 39.00, a PEG ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts' consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the firm posted $2.09 EPS. As a group, sell-side analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.62%. This is a boost from Danaher's previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. Danaher's payout ratio is presently 24.24%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of the business's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company's stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 11.10% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on DHR shares. The Goldman Sachs Group set a $250.00 target price on shares of Danaher in a report on Wednesday, January 15th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $277.00 target price (down from $299.00) on shares of Danaher in a report on Thursday, January 30th. Bank of America raised Danaher from a "neutral" rating to a "buy" rating and set a $290.00 price objective on the stock in a research report on Friday, December 13th. Jefferies Financial Group decreased their target price on Danaher from $285.00 to $260.00 and set a "buy" rating for the company in a research report on Wednesday, January 29th. Finally, Wells Fargo & Company reduced their price target on shares of Danaher from $280.00 to $240.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.